Mirvaso Now Available in the UK

Mirvaso (brimonidine) 3mg/g gel, an alpha-2 adrenergic agonist indicated for the symptomatic treatment facial erythema associated with rosacea in adult patients, is now available in the UK.

The active ingredient, brimonidine, restricts excessive blood flow to the upper layers of the skin. The topical gel is applied to the forehead, chin, nose and cheeks, and can reduce facial redness for up to 12 hours. Mirvaso offers a new and effective management option for a commonly misunderstood inflammatory skin condition.

Dr. Anton Alexandroff, Consultant Dermatologist at University Hospitals Leicester, said: "Rosacea is often misunderstood and until now we have been extremely limited in the options we can offer people suffering from facial redness. Typically the symptoms associated with rosacea get worse if left untreated so it's key that we recognize and treat this condition."

Dr. Ellie Cannon, General Practitioner, added: "Many people underestimate the impact of the flushing and redness associated with rosacea: if it is not appropriately managed it can severely impact a person's life, causing anxiety, embarrassment, low self-esteem and isolation. It is often discounted simply as blushing but the sad truth is that people are judged negatively as a result of this very visible condition."